Ariosa Diagnostics, Inc.
http://www.ariosadx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ariosa Diagnostics, Inc.
US PTO's Patent Eligibility Guidance Draws Industry Plaudits, Request For More Specifics
BIO, PhRMA, Novartis, Amgen, and Genentech suggest revisions to guidance on hot-button issue of subject matter patent eligiblity; patent owners group says 'best approach' is to enact legislation to restore patent eligibility law.
Illumina Awarded $26.7m In Patent Row
The verdict resolves an intellectual property dispute in which Illumina alleged Ariosa was violating Illumina's patents on prenatal genetic testing technology.
Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
The Gray Sheet spoke to Roche Molecular Diagnostic's top researcher, Walter Koch, about the promise of liquid biopsy soon after FDA approved its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
Company Information
- Other Names / Subsidiaries
-
- Aria Diagnostics